First‐line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Haematology

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.0902-4441.2005.t01-1-EJH2520.xPMID 16480429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone remodelation markers are useful in the management of monoclonal gammopathies.

  2004cited by this paper
• Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.

  2004cited by this paper
• Glucocorticoid-Induced Osteoporosis

  2004cited by this paper
• First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

  2004cited by this paper
• Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma

  2004cited by this paper
• Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.

  2004cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• Treatment of plasma cell dyscrasias with thalidomide and its derivatives.

  2003cited by this paper
• The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide

  2003cited by this paper
• Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy

  2003influential reference
• Single versus double autologous stem-cell transplantation for multiple myeloma.

  2003cited by this paper
• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

  2003cited by this paper
• Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Myeloma interacts with the bone marrow microenvironment 
to induce osteoclastogenesis and is dependent on osteoclast activity

  2002cited by this paper
• Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.

  2002cited by this paper
• Bone resorption parameters [carboxy‐terminal telopeptide of type‐I collagen (ICTP), amino‐terminal collagen type‐I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma

  2002cited by this paper
• Whole-body (18)F-FDG PET identifies high-risk myeloma.

  2002cited by this paper
• Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

  2001cited by this paper
• Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients.

  2001cited by this paper
• Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.

  2001cited by this paper
• Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis.

  2001cited by this paper
• Multiple myeloma

  2001cited by this paper
• The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

  2001cited by this paper
• Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

  2001cited by this paper
• Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

  2001cited by this paper
• Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

  2000influential reference
• Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

  2000cited by this paper
• Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.

  2000cited by this paper
• Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

  2000cited by this paper
• Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey

  1999cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

  1998cited by this paper
• Multiple myeloma.

  1997cited by this paper
• Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.

  1997cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• Osteoblast stimulation in multiple myeloma lacking lytic bone lesions

  1990influential reference
• DRUG THERAPY OF MULTIPLE MYELOMA.

  1964cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Tubular specific glutathione peroxidase 3 deletion exacerbates kidney damage in IRI-AKI mice.

  2025cites this paper
• The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma

  2024cites this paper
• Current application of dexamethasone-incorporated drug delivery systems for enhancing bone formation

  2023cites this paper
• Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study

  2022cites this paper
• IFN-β mediates the anti-osteoclastic effect of bisphosphonates and dexamethasone

  2022cites this paper
• A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives

  2022cites this paper
• Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

  2021cites this paper
• Molecular mechanisms, current management and next generation therapy in myeloma bone disease

  2018cites this paper
• Bisphosphonates in multiple myeloma: an updated network meta-analysis.

  2017cites this paper
• Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma

  2016cites this paper
• Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment

  2016cites this paper
• Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease

  2016cites this paper
• Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study

  2015cites this paper
• Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.

  2015cites this paper
• The prognostic role of bone turnover markers in multiple myeloma patients: The impact of their assay. A systematic review and meta-analysis.

  2015cites this paper
• Treatment of multiple myeloma bone disease: experimental and clinical data

  2015cites this paper
• Myeloma: A malignant disorder of bone and soft tissue

  2014cites this paper
• Management of bone disease in multiple myeloma

  2014cites this paper
• Sotatercept in patients with osteolytic lesions of multiple myeloma

  2014cites this paper
• VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

  2014cites this paper
• Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

  2014cites this paper
• The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

  2014cites this paper
• Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients.

  2014cites this paper
• Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

  2013cites this paper
• Effects of proteasome inhibitors on bone cancer.

  2013cites this paper
• Thalidomide affects the skeletal system of young rats.

  2013cites this paper
• Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement

  2013cites this paper
• The Effect of Novel Anti-myeloma Agents on Bone Metabolism

  2013cites this paper
• Prevention and Treatment of Myeloma Bone Disease

  2012cites this paper
• Effects of thalidomide on the development of bone damage caused by prednisolone in rats

  2012cites this paper
• Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy

  2012cites this paper
• Zoledronic Acid

  2012cites this paper
• Effects of thalidomide on the development of bone damage caused by prednisolone in rats.

  2012cites this paper
• Bisphosphonates in multiple myeloma: a network meta-analysis.

  2012cites this paper
• Bisphosphonates in multiple myeloma.

  2010cites this paper
• The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

  2010cites this paper
• Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*

  2010cites this paper
• Biochemical Markers of Bone Remodeling in Multiple Myeloma

  2010cites this paper
• Potential Role of IMiDs and Other Agents as Therapy for Myeloma Bone Disease

  2010cites this paper
• Pathogenesis and management of myeloma bone disease

  2009cites this paper
• The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

  2009cites this paper
• Thalidomide affects the skeletal system of ovariectomized rats

  2009cites this paper
• Meta-Analysis in context: Chemotherapy versus Chemotherapy combined with Bisphosphonate Therapy in Multiple Myeloma Patients

  2009cites this paper
• Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease

  2009cites this paper
• Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

  2009cites this paper
• Metastasis: a therapeutic target for cancer

  2008cites this paper
• Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

  2008cites this paper
• Soluble molecules and bone metabolism in multiple myeloma: a review.

  2008cites this paper
• The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

  2008cites this paper
• Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

  2008cites this paper
• The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

  2007cites this paper
• Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

  2007cites this paper
• The safety of zoledronic acid

  2007cites this paper
• Myeloma bone disease and proteasome inhibition therapies.

  2007cites this paper
• Laser literature watch.

  2006cites this paper
• Laser Literature Watch

  2006cites this paper